| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.sfil.in | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 582.19 Cr. | |
| Earnings per share (EPS) | 0.37 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | 19.96 | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 35.15 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 2.25 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 3.27 | Calculated using Price: 7.37 |
| Dividend Yield | 0.00 | Period Ending 2020-03 |
| No. of Shares Subscribed | 79.00 Cr. | 789,952,180 Shares |
| FaceValue | 1 | |
| Company Profile | ||
|
Syncom Formulations (India) Ltd was originally incorporated as Syncom Formulations (India) Private Limited in the state of Maharashtra on June 21, 1988 under the Companies Act, 1956. Further the status of company was changed to public limited company and thereby name of company changed to Syncom Formulations (India) Limited and a fresh certificate of change of name obtained on July 9, 1992. The company was promoted by Kedarmal Bankda, Ajay Kumar Bankda & Vijay Kumar Bankda for manufacturing, marketing, dealership, importing, exporting & job work of pharmaceuticals, medicinal and other Industrial preparation & formulations under its own brands in ethical, OTC, generic and herbal market segment. The company came out with its Initial Public Offering in the Year 1994 hence obtained listing at BSE, DSE, ASE and MSE. However company has voluntarily de-listed its shares from ASE on July 8, 2004, MPSE on May 29, 2008 & DSE on September 2, 2004. The company is engaged in the business of pharmaceutical formulations. It manufactures range of products in various dosage forms and markets them in various countries. In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures Injectibles, inhalers and ear/eye drops. In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in January 1994 was completed in 1995. During the year 1997-98, the company has further diversified into ethical operations by introducing the range of prescription formulations. During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company introduced products in the generic, OTC and ethical divisions. During the year 2007-08 the company has further completed modernization and expansion of project in Pithampur unit, District Dhar, M.P with a total investment of Rs. 1516.62 Lakh. Today, SFL stands as one of the fastest growing pharmaceutical company operating in more than 35 countries worldwide and has more than 150 products in various dosage forms which include tablets, capsules, dry syrups, and ointments/creams, dry powder Injections and ampoules and wide range of herbal products. Syncom was keeping pace with the changing pharmaceutical scenario ventured into International market a decade ago. The International operations are managed from its International division located in Mumbai, commercial capital of India. Syncom today promotes all its generic, herbal and OTC range of products in the markets where it operates. Syncom's presence is felt in Asia, Africa, CIS, and Russia and Latin American countries. Mumbai Office also houses the Regulatory Affairs Department, which is well equipped with modern library, reference documents, and all other facilities to provide world-class registration dossiers. Syncom's vision to globalise its herbal range of product has been vindicated by the excellent acceptance of these products by customers world over. Syncom has taken efforts to bring to mankind the goodness of AYURVEDA, the traditional Indian medicinal science through its unique range of herbal products used for various therapeutic and prophylactic purposes. Millions of healthy patients world wide, stand testimony to the alleviation of various disorders and improvement in their quality of life with products. The company presently exports goods to Guinea, Ghana, Kenya, Uganda, Sudan, Russia, Maldova, Tanzania, Africa, Azberjan, Nepal and Srilanka. The company has been approved as a supplier to reputed hospitals and regulatory agencies including Central Medical Stores Organization of Gujarat Govt, Directorate of health services of Delhi Govt. and Central Govt. and supply to and registration of defense services is in its final stages. This results in generating substantial sales volume. Keeping in view the shifting consumer preferences for the use of herbal products, the company is aggressively manufacturing and marketing its herbal products like Colo Vaporex, Colo Inhaler, Edicare, Attom Megacaps, Ecziguard and Yas antacid salt. In 2012 Company incorporated a Wholly Owned Subsidiary Company in the name of "TRADE ZONE FZE" in the United Arab Emirates. Product range of the company includes: Generic Herbal Branded
Branded Allopathic
Achievements/ recognition:
|
||
Company Profile
Syncom Formulations (India) Ltd was originally incorporated as Syncom Formulations (India) Private Limited in the state of Maharashtra on June 21, 1988 under the Companies Act, 1956. Further the status of company was changed to public limited company and thereby name of company changed to Syncom Formulations (India) Limited and a fresh certificate of change of name obtained on July 9, 1992.
The company was promoted by Kedarmal Bankda, Ajay Kumar Bankda & Vijay Kumar Bankda for manufacturing, marketing, dealership, importing, exporting & job work of pharmaceuticals, medicinal and other Industrial preparation & formulations under its own brands in ethical, OTC, generic and herbal market segment. The company came out with its Initial Public Offering in the Year 1994 hence obtained listing at BSE, DSE, ASE and MSE. However company has voluntarily de-listed its shares from ASE on July 8, 2004, MPSE on May 29, 2008 & DSE on September 2, 2004.
The company is engaged in the business of pharmaceutical formulations. It manufactures range of products in various dosage forms and markets them in various countries. In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures Injectibles, inhalers and ear/eye drops. In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in January 1994 was completed in 1995.
During the year 1997-98, the company has further diversified into ethical operations by introducing the range of prescription formulations. During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company introduced products in the generic, OTC and ethical divisions. During the year 2007-08 the company has further completed modernization and expansion of project in Pithampur unit, District Dhar, M.P with a total investment of Rs. 1516.62 Lakh.
Today, SFL stands as one of the fastest growing pharmaceutical company operating in more than 35 countries worldwide and has more than 150 products in various dosage forms which include tablets, capsules, dry syrups, and ointments/creams, dry powder Injections and ampoules and wide range of herbal products.
Syncom was keeping pace with the changing pharmaceutical scenario ventured into International market a decade ago. The International operations are managed from its International division located in Mumbai, commercial capital of India. Syncom today promotes all its generic, herbal and OTC range of products in the markets where it operates. Syncom's presence is felt in Asia, Africa, CIS, and Russia and Latin American countries. Mumbai Office also houses the Regulatory Affairs Department, which is well equipped with modern library, reference documents, and all other facilities to provide world-class registration dossiers.
Syncom's vision to globalise its herbal range of product has been vindicated by the excellent acceptance of these products by customers world over. Syncom has taken efforts to bring to mankind the goodness of AYURVEDA, the traditional Indian medicinal science through its unique range of herbal products used for various therapeutic and prophylactic purposes. Millions of healthy patients world wide, stand testimony to the alleviation of various disorders and improvement in their quality of life with products. The company presently exports goods to Guinea, Ghana, Kenya, Uganda, Sudan, Russia, Maldova, Tanzania, Africa, Azberjan, Nepal and Srilanka.
The company has been approved as a supplier to reputed hospitals and regulatory agencies including Central Medical Stores Organization of Gujarat Govt, Directorate of health services of Delhi Govt. and Central Govt. and supply to and registration of defense services is in its final stages. This results in generating substantial sales volume. Keeping in view the shifting consumer preferences for the use of herbal products, the company is aggressively manufacturing and marketing its herbal products like Colo Vaporex, Colo Inhaler, Edicare, Attom Megacaps, Ecziguard and Yas antacid salt.
In 2012 Company incorporated a Wholly Owned Subsidiary Company in the name of "TRADE ZONE FZE" in the United Arab Emirates.
Product range of the company includes:
Generic Tablets
Herbal Branded
Branded Allopathic
Achievements/ recognition:
| 1 Day |
|
+4.99% |
| 1 Week |
|
-11.95% |
| 1 Month |
|
-12.37% |
| 3 Month |
|
+34.24% |
| 6 Month |
|
+128.88% |
| 1 Year |
|
+330.99% |
| 2 Year |
|
+857.14% |
| 5 Year |
|
+144.04% |
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | 4.24 | 6.60 | 10.19 | 9.99 | 9.91 | 9.56 | 7.33 | 8.71 | 10.24 | |
| Return on Capital Employed (%) | 6.76 | 9.98 | 15.29 | 15.55 | 14.72 | 13.58 | 9.43 | 9.37 | 12.32 | |
| Return on Assets (%) | 3.10 | 4.76 | 6.95 | 6.82 | 6.41 | 5.93 | 4.90 | 6.34 | 7.92 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 84 | 88 | 95 | 100 | 109 | 114 | 122 | 133 | 146 | |
| Non Curr. Liab. | 7 | 8 | 7 | 6 | 6 | 8 | 9 | 8 | 7 | |
| Curr. Liab. | 23 | 29 | 42 | 37 | 66 | 56 | 43 | 36 | 31 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 113 | 124 | 144 | 143 | 181 | 179 | 174 | 176 | 184 | |
| Non Curr. Assets | 63 | 63 | 66 | 59 | 89 | 92 | 93 | 95 | 94 | |
| Curr. Assets | 50 | 62 | 78 | 83 | 92 | 87 | 81 | 81 | 90 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 113 | 124 | 144 | 143 | 181 | 179 | 174 | 176 | 184 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 118 | 115 | 151 | 173 | 184 | 185 | 159 | 187 | 206 | |
| Other Income | 1 | 1 | 1 | 2 | 3 | 3 | 4 | 5 | 5 | |
| Total Income | 119 | 116 | 152 | 175 | 187 | 188 | 163 | 192 | 211 | |
| Total Expenditure | -110 | -104 | -135 | -155 | -167 | -168 | -147 | -175 | -189 | |
| PBIDT | 9 | 12 | 17 | 20 | 19 | 19 | 16 | 17 | 22 | |
| Interest | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | |
| Depreciation | -3 | -3 | -3 | -3 | -3 | -3 | -4 | -4 | -4 | |
| Taxation | -2 | -3 | -5 | -6 | -6 | -5 | -3 | -2 | -3 | |
| Exceptional Items | -1 | 0 | 0 | 0 | 0 | |||||
| PAT | 4 | 6 | 9 | 10 | 10 | 11 | 9 | 11 | 14 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 6 | 6 | 7 | 0 | 24 | 17 | -2 | 4 | -1 | |
| Cash Fr. Inv. | -5 | 0 | -4 | 1 | -23 | -8 | -2 | 2 | 1 | |
| Cash Fr. Finan. | -1 | -6 | -1 | 1 | -2 | -2 | -2 | 0 | 0 | |
| Net Change | 1 | -1 | 2 | 2 | -1 | 6 | -6 | 7 | 1 | |
| Cash & Cash Eqvt | 5 | 4 | 5 | 7 | 6 | 7 | 1 | 7 | 8 |
|
Wed, 28 Jul 2021
Submission Of Disclosure Under Regulation 23(9) Of SEBI (LODR) Regulations 2015 Regarding Disclosure Of Related Party Transactions For The Half Year Ended 31St March 2021. Pursuant to Regulation 23(9) of SEBI (LODR) Regulations 2015 as amended from time to time we are pleased to submit the Disclosure of Statement of Related Party Transactions for the half year ended 31st March 2021. The same is also published on the website of the Company www.sfil.in You are requested to please consider and take on record the same. |
||||||||||||||
|
Wed, 21 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 In accordance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018 (erstwhile Reg. 54 of SEBI (Depositories and Participant) Regulations 1996) for the period starting from 1st April 2021 to 30th June 2021 based on the certificate received (enclosed herewith) received from our Registrar and share Transfer Agent M/s Ankit Consultancy Pvt. Ltd. You are requested to please take on record the above said document for your reference & further needful. |
||||||||||||||
|
Tue, 20 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
|
| Fri, 30 Jul 2021 |
Strongly Outperforming Benchmark Index
|
Strongly Outperforming Sectoral Index
|
Both SRS And ARS Above Zero
|
ADX Crossing 25 From Below
|
Close Crossing Lower Bollinger Band From Below
|
Equities
M.F.
Sectors